海利生物(603718) - 2017 Q3 - 季度财报
HILEHILE(SH:603718)2017-10-27 16:00

Financial Performance - Net profit attributable to shareholders increased by 17.60% to CNY 83,849,652.70 for the first nine months of the year[5] - Basic and diluted earnings per share increased by 18.18% to CNY 0.13[6] - The company’s total equity increased to ¥1,077,069,834.56 from ¥1,007,754,215.24 year-over-year[27] - The net profit for Q3 2017 reached ¥31,008,527.76, representing an increase of 22.0% from ¥25,239,084.47 in Q3 2016[33] - The total profit for the first nine months of 2017 was ¥113,099,985.03, an increase of 17.6% compared to ¥96,178,603.38 in the same period of 2016[32] Revenue and Operating Income - Operating revenue decreased by 4.66% to CNY 238,515,336.98 for the first nine months of the year[5] - Total operating revenue for Q3 2017 was ¥91,770,891.75, a decrease of 2.4% from ¥93,748,028.78 in Q3 2016[29] - The company’s operating revenue for Q3 2017 was ¥81,953,950.07, a decrease of 12.6% compared to ¥93,748,028.78 in Q3 2016[32] - Other operating income increased significantly by 719.39% to ¥15,108,235.89, attributed to higher fiscal subsidies received[11] Assets and Liabilities - Total assets increased by 7.23% to CNY 1,586,915,481.35 compared to the end of the previous year[5] - Total liabilities increased from 474.55 million yuan at the beginning of the year to 533.29 million yuan[24] - The company's total current assets amounted to 827.85 million yuan, slightly down from 828.52 million yuan at the beginning of the year[22] - Total assets as of Q3 2017 amounted to ¥1,247,343,945.73, up from ¥1,166,259,259.60 in the previous year[27] Cash Flow - Cash flow from operating activities decreased by 2.84% to CNY 59,774,438.37 for the first nine months of the year[5] - The net cash flow from operating activities for the first nine months of 2017 was ¥85,859,115.81, an increase of 9.6% compared to ¥78,186,474.58 in the same period last year[40] - The company reported cash inflows from investment activities of ¥2,088,195,253.31 for the first nine months of 2017, significantly higher than ¥940,182,380.13 in the same period of 2016[36] - The cash flow from operating activities for the third quarter was ¥85,859,115.81, compared to ¥78,186,474.58 in the same quarter last year, showing a positive trend[40] Expenses - Financial expenses surged by 303.34% to ¥6,515,574.84, primarily due to interest expenses from subsidiary borrowings[11] - Cash paid for purchasing goods and receiving services rose by 41.81% to ¥72,945,772.03, reflecting increased operational procurement expenses[11] - The company’s sales expenses for Q3 2017 were ¥28,110,876.54, a decrease of 26.6% compared to ¥38,313,862.95 in Q3 2016[32] Investments - Investment income rose by 66.52% to ¥11,959,752.05, mainly driven by increased financial management income[11] - The company achieved an investment income of ¥10,506,301.44 for the first nine months of 2017, compared to ¥6,724,880.13 in the same period of 2016[32] - The total amount of entrusted wealth management during the reporting period was 117.6 million yuan, with a total of 15 transactions[17] Inventory and Receivables - Accounts receivable increased by 195.86% to CNY 31,817,735.98 due to increased credit sales[10] - Inventory increased by 114.35% to CNY 86,073,246.41 due to increased material reserves from subsidiaries[10] - Accounts receivable increased significantly from 10.75 million yuan at the beginning of the year to 31.82 million yuan[22] - Inventory rose from 40.15 million yuan at the beginning of the year to 86.07 million yuan[22] Financing Activities - The company raised ¥150,000,000.00 through borrowings, compared to no borrowings in the same period last year, indicating a shift in financing strategy[41] - Total cash outflow from financing activities was ¥176,290,700.00, up from ¥28,000,000.00 in the previous year, reflecting increased dividend payments and debt repayments[41]

HILE-海利生物(603718) - 2017 Q3 - 季度财报 - Reportify